Functional and structural renal changes in the early stages of obesity

Contributions to Nephrology

Volumn 151, Issue , 2006, Pages 135-150

  Thakur, Vashu ^a   Morse, Stephen ^a   Reisin, Efrain ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; HUMAN; KIDNEY; KIDNEY DISEASE; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; HUMANS; KIDNEY; KIDNEY DISEASES; OBESITY;

EID: 33748039460     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000095325     Document Type: Review

References (98)

1. Abdel-Halim R: Obesity: 1000 years ago. Lancet 2005;366:204.
2. Flegal K, et al: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-1727.
3. American Academy of Pediatrics, Committee on Nutrition: Prevention of pediatric overweight and obesity. Pediatrics 2003;112:424-430.
4. Ogden C, et al: Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002;288:1728-1732.
5. Macedo M, Trigueiros D, de Freitas F: Prevalence of high blood pressure in children and adolescents: Influence of obesity. Rev Port Cardiol 1997;16:27-28.
6. Freedman D, et al: The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 1999;103:1175-1182.
7. Sorof J, et al: Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 2004;113:475-482.
8. Kortelainen M: Adiposity, cardiac size and precursors of coronary atherosclerosis in children: a prospective study of 210 violent deaths. Int J Obes Relat Metab Disord 1997;21:691-697.
9. American Diabetes Association: Type 2 diabetes in children and adolescents. Diabetes Care 2000;23:381-389.
10. Fagot-Campagna A, et al: Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000;136:664-672.
11. Holl R, et al: Prevalence and clinical characteristics of patients with non-type 1 diabetes in the pediatric age range: analysis of a multicenter database including 20,410 patients from 148 center in Germany and Austria. Diabetologia 2003;46(suppl 2):A26.
12. Ehtisham S, et al: Prevalence of type 2 diabetes in children in Birmingham. BMJ 2001;322:1428.
13. Wei J, et al: National surveillance for type 2 diabetes mellitus in Taiwanese children. JAMA 2003;290:1345-1350.
14. Braun B, et al: Diabetes Care 1996;19:472-479.
15. Henegar J, et al: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001;12:1211-1217.
16. Gelber R, et al: Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005;46:871-880.
17. Coresh J, et al: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey. Am J Kidney Dis 2003;41:1-12.
18. Hoehner C, et al: Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 2000;13;1626-1634.
19. Chen J, et al: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004;140:167-174.
20. Palaniappan L, Carnethon M, Fortmann S: Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003;16:952-958.
21. Chen J, et al: Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003;14:469-477.
22. Fox C, et al: Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844-850.
23. Zhang R, Reisin E: Obesity-hypertension: The effects on cardiovascular and renal systems. J Hypertens 2000;13:1308-1314.
24. Verani R: Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis 1992;20:629-634.
25. Kambham N, et al: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498-1509.
26. USRDSU: 15th Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
27. Hall J: Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension 1994;23:381-394.
28. Hall J, et al: Obesity-induced hypertension: Renal function and systemic hemodynamics. Hypertension 1993;22:292-299.
29. Reisin E, et al: Renal hemodynamic studies in obesity hypertension. J Hypertens 1987;5:397-400.
30. Ribstein J, Cailar G, Mirman A: Combined renal effects of overweight and hypertension. Hypertension 1995;26:610-615.
31. Nyengaard J, Bendtsen T: Glomerular number and size in relation to age, kidney weight, and body surface area in normal man. Anat Rec 1992;232:194-201.
32. Chagnac A, et al: Glomerular hemodynamics in severe obesity. Am J Physiol Renal Phsiol 2000;278:f817-f822.
33. Reisin E: Obesity and the kidney connection. Am J Kidney Dis 2001;38:1129-1134.
34. Arnold M, et al: Obesity associated renal medullary changes. Lab Invest 1994;70:156A.
35. Zhang R, Thakur V, Reisin E: Renal and cardiovascular considerations for the nonpharmacological and pharmacological therapies of obesity-hypertension. J Human Hypertens 2002;16:819-827.
36. Morales E, et al: Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003;41:319-327.
37. Praga M, et al: Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000;58:2111-2118.
38. Lackland D, et al: Low birth weights contribute to high rates of early-onset chronic renal failure in the southeastern United States. Arch Intern Med 2000;160:1472-1476.
39. Bagby S: Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol 2004;15:2775-2791.
40. Osmond C, Barker D: Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. Environ Health Perspect 2000;108(suppl 3):545-553.
41. Hall J: Mechanism of abnormal renal sodium handing in obesity hypertension. Am J Hypertens 1997;10:49S-55S.
42. Kojima M, et al: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-660.
43. Wortley KE, et al: Absence of ghrelin protects against early-onset obesity. J Clin Invest 2005;115:3573-3578.
44. Sun Y, Ahmed S, Smith RG: Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003;23:7973-7981.
45. Sun Y, et al: Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 2004;101:4679-4684.
46. Zigman J, et al: Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005;115:3564-3572.
47. Schwartz M, et al: Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996;98:1101-1106.
48. Wisse B: The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:2792-2800.
49. Wolf G, et al: Leptin and renal disease. Am J Kidney Dis, 2002;39:1-11.
50. Havel P: Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002;13:51-59.
51. Mulyadi L, et al: Body fat distribution and total body fat as risk factors for microalbuminuria in the obese. Ann Nutr Metab 2001;45:67-71.
52. Steppan C, et al: The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
53. Kamijo A, et al: Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 2002;62:1628-1637.
54. Unger R: Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144:5159-5165.
55. The catastrophic failure of public health [editorial]. Lancet 2004;363:745.
56. Corbett S: A Ministry for the Public's Health: an imperative for disease prevention in the 21 st century? Med J Aust 2005;183:254-257.
57. Batey L, et al: Summary measures of the insulin resistance syndrome are adverse among Mexican-American versus non-Hispanic white children: the Corpus Christi Child Heart Study. Circulation 1997;96:4319-4325.
58. Reaven P, et al: Cardiovascular disease insulin risk in Mexican-American and Anglo-American children and mothers. Pediatrics 1998;101:E12.
59. Kwon H, et al: Prevalence and clinical characteristics of the metabolic syndrome in middle-aged Korean adults. Korean J Intern Med 2005;20:310-316.
60. Mykkanen L, et al: Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998;47:793-800.
61. Castro J, et al: Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep 2003;5:393-401.
62. Mangrum A, Bakris G: Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. J Diabetes Complications 1997;11:352-357.
63. McFarlane S, Banerji M, Sowers J: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713-718.
64. Yusuf S, et al: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
65. Lindholm L, et al: Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002;20:1879-1886.
66. Langsford H, et al: Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA 1985;253:657-669.
67. Reisin E: Obesity hypertension: nonpharmacologic and pharmacologic therapeutic modalities; in Laragh JH, Brenner B (eds): Hypertension: Pathophysiology Diagnosis, and Management New York, Raven Press, 1995, 2683-2691.
68. Sinaiko A, et al: Insulin resistance syndrome in childhood: associations of the euglycemic insulin clamp and fasting insulin with fatness and other risk factors. J Pediatr 2001;139:700-707.
69. Gunther A, Buyken A, Kroke A: The influence of habitual protein intake in early childhood on BMI and age at adiposity rebound: results from the DONALD Study. Int J Obes (Lond) 2006 [Epub ahead of print].
70. Hakanen M, et al: Development of overweight in an atherosclerosis prevention trial starting in early childhood. The STRIP study. Int J Obes (Lond) 2006;30:618-626.
71. Oken E, et al: Associations of maternal prenatal smoking with child adiposity and blood pressure. Obes Res 2005;13:2021-2028.
72. Richards R, et al: Effects of dehydroepiandrosterone and quinapril on nephropathy in obese Zucker rats. Kidney Int 2001;59:37-43.
73. Zatz R, et al: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930.
74. Khan B, et al: Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care 2004;27:1712-1715.
75. Schupp M, et al: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-alpha activity. Circulation 2004;109:2054-2057.
76. Reisin E, et al: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997;30:140-145.
77. Lewis E, et al: Collaborative Study Group: renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
78. Pohl M, et al: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005;16:3027-3037.
79. Julius S, Majahalme S, Palatini P: Antihypertensive treatment of patients with diabetes and hypertension. Am J Hypertens 2001;14(pt 2):310S-316S.
80. Guan Y: PPAR family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004;15:2801-2815.
81. Guan Y, Breyer, MD: Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001;60:14-30.
82. Guan Y, Breyer M: Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease. Minerva Urol Nephrol 2002;54:65-79.
83. Park C, et al: A PPAR alpha agonist improves diabetic nephropathy in db/db mice. Am Soc Nephrol 2003;14:393A.
84. Fried L, Orchard T, Kasiske B: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260-269.
85. Isshiki K, et al: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000;49:1022-1032.
86. McCarthy K, et al: Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000;58:2341-2350.
87. Baylis C, et al: Peroxisome proliferator-activated receptor γagonist provides superior renal protection versus angiotension-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003;307:854-860.
88. Bakris G, et al: Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17:7-12.
89. Nakamura T, et al: Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000;14:250-254.
90. Wolffenbuttel B, et al: Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17:40-47.
91. Imano E, et al: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21:2135-2139.
92. Guo B, et al: Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004;53:200-208.
93. Chana R, Lewington A, Brunskill N: Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cell: thiazolidinediones are partial PPAR gamma agonist. Kidney Int 2004;65:2081-2090.
94. Benson S, et al: Identification of telmisartan as a unique angiotensin 2 receptor antagonist with selective PPAR-modulating activity. Hypertension 2004;43:993-1002.
95. Hao C, et al: Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress. J Biol Chem 2002;277:21341-21345.
96. Hegarty B, et al: PPAR activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo - a study using the novel PPAR (alpha)/(gamma) agonist Tesaglitazar. Endocrinology 2004;145:3158-3164.
97. Knowler W, et al: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
98. Zhang R, et al: Kidney disease and the metabolic syndrome. Am J Med Sci 2005;330:319-325.